RT Journal Article
SR Electronic
T1 Efficacy of IP-10 as a biomarker for monitoring tuberculosis therapy
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2778
VO 42
IS Suppl 57
A1 Ji Young Hong
A1 GyeongSeo Jung
A1 Young Mi Kim
A1 Hye Jon Lee
A1 Sang Nae Cho
A1 Eu Dong Hwang
A1 Young Jae Kim
A1 In Seon Lee
A1 Se Kyu Kim
A1 Joon Chang
A1 Chul Min Ahn
A1 Young Ae Kang
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2778.abstract
AB Objective: The objective of this study was to evaluate serum IP-10 and TB antigen dependent IP-10 secretion as biomarkers for monitoring TB treatment.Methods: Thirty-two patients with active tuberculosis were enrolled and the patients were classified into two groups by the presence of cavity or positive sputum culture after two months of anti TB treatment. In this exploratory study, we assessed the changes in serum IP-10, TB antigen dependent IP-10 and IFN-γ response to QFT-GIT antigens at the time of diagnosis and after treatment completion.Results: Significant changes between at the time of TB diagnosis and at therapy completion were observed in the serum IP-10(P<0.001, median: 140.4 pg/ml, 105.7 pg/ml) and TB antigen dependent IP-10(P<0.001, median: 869.7 pg/ml, 815.0pg/ml). The proportion of TB antigen dependent IP-10 responders did not significantly change between baseline and therapy completion(P=0.180), whereas the proportion of serum IP-10 responders significantly changed(P=0.008). The reversion rate is prominent in low risk group than the moderate/high risk group. The majority of patients didn’t exhibit QFT-GIT reversion.Conclusions: Serum IP-10 and IP-10 response to QFT-GIT antigen might be a useful biomarker for monitoring therapy efficacy in patients with active TB. Further studies in larger cohorts are needed to confirm the consistency of this result and identify the appropriate cutoffs.